Updated: a graphic tracker of key developments from the leading vaccine candidates.
When will a vaccine against COVID-19 be ready? That's what everybody wants to know, because without one, the world remains at the mercy of the SARS-CoV-2 pandemic.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
